https://www.businesswire.com/news/home/20250403023818/en/Sangamo-Therapeutics-Announces-Capsid-License-Agreement-With-Lilly-to-Deliver-Genomic-Medicines-for-Diseases-of-the-Central-Nervous-System
SANGAMO THERAPEUTICS ANNOUNCES CAPSID LICENSE AGREEMENT WITH LILLY TO DELIVER GENOMIC MEDICINES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM
sangamo therapeuticslicense agreementannouncescapsidlilly
https://www.technologynetworks.com/proteomics/news/novo-nordisk-and-sangamo-biosciences-announce-agreement-203925
Sangamo will provide its ZFP technology for Novo Nordisk to evaluate for use in the field of enhanced protein production.
novo nordisksangamo biosciencesannounceagreementtechnology
https://www.sangamobrewing.com/
Sangamo Brewing located in Chatham, IL, is a premier brewpub serving Springfield, Rochester, New Berlin, and surrounding areas. Come visit our Sangamo Brewery...
sangamobrewingchathamil
https://www.pissedconsumer.com/company/sangamo/customer-service.html
How to contact Sangamo customer support at phone number? Call or write an email to sales@espuk.com to resolve Sangamo issues. Visit the company website...
customer servicephone numbersangamoemail
https://www.statnews.com/2025/09/18/sangamo-fabry-therapy-geoff-porges-fda/
Sep 18, 2025 - In this week's edition of "Adam's Biotech Scorecard," Adam looks at the prospects for Sangamo and speaks with Porges, now a Wall Street...
partner searchsangamofabrytherapylooks
https://www.sangamo.com/
Feb 28, 2026 - Sangamo uses a multi-platform approach to gene-based therapeutics with industry leading technologies in gene therapy, gene editing, cell therapy and gene...
sangamo therapeuticsincpioneeringgeneticcures
https://www.businesswire.com/news/home/20200730005166/en/Sangamo-Announces-Global-Collaboration-With-Novartis-to-Develop-Genomic-Medicines-for-Autism-and-Other-Neurodevelopmental-Disorders
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has executed a global licensing collaboration agreement with N...
global collaborationsangamoannouncesnovartisdevelop
https://www.technologynetworks.com/biopharma/news/fda-grants-orphan-drug-designation-to-sangamo-194406
Sangamo Biosciences receives orphan drug designation from the FDA for SB-FIX for application of therapeutic in vivo genome editing.
orphan drug designationfdagrantssangamotechnology